OTCKing - Helping tomorrow's FORTUNE 500 companies TODAY!

Viking investments,VKIN,Profile,Summary

Viking Investments Group, VKIN, Profile, Summary

Viking Investments Group provides professional advisory and consulting services to companies undergoing or anticipating periods of rapid growth, significant change or ownership transition, and when justified, staffing, financing, and/or providing operational support to such companies. Target companies must have superior management, intimate knowledge of their particular industry and a sound business plan, along with a desire and receptiveness for specific expertise to advance the company's business objectives.

Viking’s primary focus is directed toward North America, targeting various industries,mainly in the Oil & Gas sector and other selective sectors, with appropriate diversification and balance between each.  Viking targets under-valued businesses with realistic appreciation potential and a defined exit strategy.

Current Projects

The Joffre D-3 Oil Project is located in the Leduc D-3 B Pinnacle Reef in Central Alberta, Canada (the “Joffre Project”).

Viking owns a 50% working interest in the Joffre Project which consists of 4 oil wells and one water injection well.  The wells were previously suspended. Viking and Tanager Energy Inc., Viking’s partner for this project, mobilized the first well (production commenced on April 1st, 2015), and intend to mobilize the remaining wells sequentially.

After 5 days of anticipated monitoring and operating facility adjustments, the well is now producing at a rate of 118 barrels of oil per day of 38 API gravity crude oil and 250 mcf of natural gas, totaling 160 BOE/D.  The well is a flowing oil well with a flowing wellhead pressure of 435 psi.

Viking estimates to complete the re-work of the remaining wells during the second and third quarter of 2015.

Mobilization and reactivation efforts involve, among other things, completing the re-entry and downhole pressure survey to determine the current reservoir pressure, a critical element in determining the scope and anticipated production of this suspended oil pool. The survey with respect to the first well confirmed the reservoir pressure returned to 94% of the original pressure (i.e. the pressure that existed when the pool was discovered in 1986) due to the active water drive in the pool.

Following the pressure test described above, a production test is performed to confirm the productivity of the pool.  The production test for the first well occurred between January 13th and January 15th, 2015 and the test results indicated the following:

• a stabilized production rate of 290 BOE/d (235 barrels per day of oil and 325 mcf/d of gas).

• the flowing wellhead pressure was stable at 475 psi, estimated to be a 7.7% drawdown of the reservoir. On a metric equivalent basis this is 52.5 cubic meters oil equivalent per day at 3265 kpa flowing wellhead pressure.

• The fluid produced was 100 percent high gravity oil.

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] DailyStockDeals.com

Amedica Corporation, AMDA, Profile, Summary

Amedica Corporation, AMDA, Profile, Summary

Amedica Corporation, AMDA, is a commercial biomaterial company. The Company is focused on using its silicon nitride technology platform to develop, manufacture and sell a range of medical devices. The Company markets spinal fusion products and are developing products for use in total hip and knee joint replacements.

Biomaterials are synthetic or natural materials available in a variety of forms that are used in virtually every medical specialty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. In addition, to its silicon nitride-based spinal fusion products, it markets a complementary line of non-silicon nitride spinal fusion products which allows providing surgeons and hospitals with a range of products. The Company produces its silicon nitride advanced ceramic in four forms: a fully dense, load-bearing solid, referred to as MC2; a porous bone-like cancellous structured form, referred to as CSC; a composite incorporating both its solid MC2 material and its porous CSC material intended to promote an environment for bone growth; and a coating for application onto other biomaterials.

The Company competes with Medtronic, Inc.; DePuy Synthes Companies, a group of Johnson & Johnson companies; Stryker Corporation; Biomet, Inc.; Zimmer Holdings, Inc.; Smith & Nephew plc; Aesculap Inc; CeramTec, Kyocera, and CoorTek, Inc.

OSTEOPROMOTIVE: DELIVERS ENHANCED OSTEOGENIC RESPONSE

• Enhanced osteopromotion: The surface chemistry and nanostructure topography of Si3N4 provides an optimal environment for stimulation of osteoprogenitor cells to differentiate into osteoblasts.

• Greater protein adsorption: Si3N4 demonstrates significantly greater protein adsorption (fibronectin, laminin and vitronectin) in comparison to PEEK and titanium. (1)

• Greater new bone formation: Si3N4 implants demonstrate greater new bone formation at 3, 7, 14 and 90 days compared to PEEK and titanium in in vivo study; regenerated bone associated with Si3N4 implants is 2 to 3 times that of PEEK and titanium implants at 3 months after surgery.(2)

• Increased osteointegration: Si3N4 implants demonstrate increased osteointegration at 3, 7, 14 and 90 days compared to PEEK and titanium in in vivo studies; percent of bone at Si3N4 implant interface is 2 to 6 times that of PEEK and titanium implants at 3 months after surgery.(2)

DEMONSTRATED ANTI-INFECTIVE PROPERTIES

• Superior antibacterial function: Si3N4 inhibits biofilm formation and bacterial colonization. Si3N4 demonstrates significantly lower biofilm formation at 4, 24, 48 and 72 hours as compared to PEEK and titanium; live bacteria (S. epidermidis, S. aureus, P. aeruginosa, E. coli and Enterococcus) associated with Si3N4 implants are 8 to 30 times lower than PEEK and titanium.(1)

• Demonstrated bacteriostatic agent: In in vivo studies, no infection is observed with bacteria-inoculated Si3N4 implants at 3 months, whereas both PEEK and titanium implants maintain a septic state. Si3N4 demonstrates this property even in the absence of antibiotics.(2)

EXCELLENT IMAGING PROPERTIES

• Compatible with all imaging modalities: Si3N4 implants are semi-radiolucent with clearly visible boundaries, and produce no distortion under MRI and no scattering under CT; this enables an exact view of the implant for precise intraoperative placement and postoperative fusion assessment.

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com